Decreased bone mineral density with off-label use ...[J Pediatr. 2008]

SearchDatabase nameforSearch term

Advanced Search

Warning: The NCBI web site requires JavaScript for full functionality. more...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: J Pediatr. 2008 Apr;152(4):582-4. Links

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.

Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R.

HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

5 of 6 children infected with human immunodeficiency virus (HIV) receiving Tenofovir disoproxil fumarate (TDF) experienced absolute decreases in bone mineral density (BMD). 2 pre-pubertal subjects experienced >6% BMD decreases. 1 subject was the smallest child and experienced a 27% decrease, necessitating withdrawal of TDF. Subsequently, her BMD recovered. Monitoring of children infected with HIV who require treatment with TDF is warranted.

PMID: 18346519 [PubMed - indexed for MEDLINE]

PMCID: PMC2390888

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Pediatrics. 2006 Sep; 118(3):e711-8. Epub 2006 Aug 21.

[Pediatrics. 2006]
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Pediatrics. 2005 Dec; 116(6):e846-54. Epub 2005 Nov 15.

[Pediatrics. 2005]
A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.
J Acquir Immune Defic Syndr. 2005 Dec 1; 40(4):448-50.

[J Acquir Immune Defic Syndr. 2005]
ReviewExperience with tenofovir disoproxil fumarate for antiretroviral therapy.
Expert Opin Pharmacother. 2008 May; 9(7):1197-209.

[Expert Opin Pharmacother. 2008]
ReviewTenofovir-associated nephrotoxicity in two HIV-infected adolescent males.
AIDS Patient Care STDS. 2009 Jan; 23(1):1-4.

[AIDS Patient Care STDS. 2009]
» See reviews... | » See all...

Patient Drug Information

Tenofovir (Viread®, Atripla® (as a combination product containing Efavirenz, Emtricitabine, and Tenofovir, Truvada® as a combination product containing Tenofovir and Emtricitabine))
Tenofovir is used in combination with other antiviral medications to treat human immunodeficiency virus (HIV) in patients with acquired immunodeficiency syndrome (AIDS). Tenofovir is in a class of antiviral medications c...
Source: AHFS Consumer Medication Information

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

» See more...

Display Show

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.

Related articles

Patient Drug Information

Recent Activity